Darzalex Setback In NHL Raises Stakes For First-Line Myeloma Approval

 
• By Lucie Ellis-Taitt
  
Cancer cell
Janssen/Genmab's Darzalex suffers disappointing setback in Phase II NHL studies • Source: Shutterstock

More from Clinical Trials

More from R&D